Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_assertion description "[Low-dose demethylating agents such as 5-aza-2'-deoxycytidine (decitabine, DAC) and 5-azacytidine (azacitidine, Vidaza) have been explored for the treatment of myelodysplasia, acute myeloid leukemia, and hemoglobinopathies since the early 1980s, aiming to revert a methylator phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_assertion evidence source_evidence_literature NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_assertion SIO_000772 16292549 NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_assertion wasDerivedFrom befree-20150227 NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_assertion wasGeneratedBy ECO_0000203 NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.
- befree-20150227 importedOn "2015-02-27" NP217978.RAfTpIBHpggJi-ikN-85fUG2kZHDfGFHkkXgqBMRbN-Mk130_provenance.